Aclaris Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 17.57 million compared to USD 7.75 million a year ago. Net loss was USD 1.49 million compared to USD 27.64 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.41 a year ago.

For the full year, the company reported revenue was USD 31.25 million compared to USD 29.75 million a year ago. Net loss was USD 88.48 million compared to USD 86.91 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago. Diluted loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago.